KU Hematology & Medical Oncology Review 2019
Video Player is loading.
10 seconds
Playback speed
KU ASCO 2019: Update on CLL Preferred Therapy - BR vs Ibrutinib & Ibrutinib + Rituximab vs. FCR
Comments 0
Login to view comments.
Click here to Login
